Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


25 junio 2012

Teleflex Acquires Innovative Technology to Reduce Biological Formation on Medical Devices

MDT Medical Design Tecnology. BUSINESS WIRE

Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences (Cambridge, Massachusetts), a biomedical company and spin out from Massachusetts Institute of Technology (MIT). The acquisition includes the core Semprus Sustain(TM) Technology. The transaction brings to Teleflex an innovative and patented platform technology that serves as the basis for next-generation medical devices. The technology is designed to provide the benefits of reducing complications such as thrombosis and microbial adhesion over long durations.

21 junio 2012

ReCor presents data for Paradise hypertension renal denervation system

Interventional News

ReCor Medical has reported six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the company s Paradise system. According to a company release, this is the only system for renal denervation that is based on ultrasound, not radiofrequency, energy.

19 junio 2012

Siemens SOMATOM Definition Edge Single-Source CT Cleared for Sale in U.S.

BioPortfolio

Siemens Healthcare (NYSE: SI) has announced that the SOMATOM Definition Edge single-source computed tomography (CT) system – the first single-source CT to use Siemens recently introduced Stellar Detector – has been approved for sale in the United States. With ever-greater patient volumes in the Emergency Department (ED) setting, where 40 percent(1) of CT examinations are performed, hospital demand is increasing for more efficient and cost-effective imaging solutions. With these escalating ED needs in mind, Siemens designed the SOMATOM Definition Edge CT system, which demonstrates Siemens innovation and competitiveness – goals of the Healthcare Sector s Agenda 2013 two-year global initiative.

18 junio 2012

Renal Denervation: Just How Big Is The Bandwagon?

Medlatest

There are plenty of parallels in the history of medical device development, but there’s no doubting the fact that this particular bandwagon is gathering pace at a rate not seen since the early days of coronary angioplasy, balloons, stents and all that. And it’s easy to see why, because renal denervation, despite being a recently developed therapy, does seem to be generating a fistful of good results, demonstrating immediate and sustained blood pressure reduction in patient hitherto resistant to pretty much any other form of anti-hypertensive therapy.

15 junio 2012

Is catheter-based lysis superior to intravenous lysis and surgery for massive and submassive pulmonary embolism?

Interventional News

In the Hot Topics Debate session at the Society of Interventional Radiology’s annual scientific meeting in San Francisco, USA, co-ordinated by Daniel Sze, William T Kuo and John F Angle spoke for the motion “catheter-based lysis is superior to intravenous lysis and surgery for massive and submassive pulmonary embolism”. They took on the Scott O Trerotola and Suresh Vedantham who spoke against the motion and argued that there were no data to support catheter interventions for pulmonary embolism.

15 junio 2912

Paradise™Ultrasound-Based Renal Denervation System Shows 6 Month 33mmHg BP Reduction In Resistant Hypertension Patients

Medlatest. Business Wire

Renal Denervation is one of the hottest topics in medical devices at the moment and German outfit ReCor Medical has been in the fray with its announcement of CE marking for its Paradise™ system earlier this year (details here). Now the company has reported six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the company s unique ultrasound-based system.

02 noviembre 2011

First patient enrolled into SYMPLICITY HTN-3

Vascular NEWS

Medtronic has announced the start of SYMPLICITY HTN-3, the company’s US clinical trial of the Symplicity renal denervation system for treatment-resistant hypertension. The first patient in this landmark study was enrolled at the Prairie Heart Institute at St John’s Hospital in Springfield, USA.

0 abril 2015

BTG begins sale of DC Bead and Bead Block directly to physicians

Interventional News

BTG has expanded its commercial presence in Europe in recent months by building an expert sales force to promote the approved uses of its products in major European markets. This team has been selling BTG’s radioembolization product TheraSphere and will also sell DC Bead and Bead Block, the company’s complementary interventional oncology products.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.